High oxidative stress in patients with stable coronary heart disease

Atherosclerosis

Volumn 168, Issue 1, 2003, Pages 99-106

  Weinbrenner, Tanja ^a   Cladellas, Mercedes ^b   Isabel Covas, Maria ^a,c   Fitó, Montserrat ^a   Tomás, Marta ^a   Sentí, Mariano ^a,d   Bruguera, Jordi ^b   Marrugat, Jaume ^a,e   Alcántara, Mercedes ^f   De La Torre, Carmen ^f   De La Torre, Rafael ^f   Farré, Magí ^f   Gimeno, Eva ^f   Illa, Jame ^f   Lamuela Reventós, Rosa ^f   López Sabater, Carmen ^f   Maití, Julio ^f   Miró, Elisabet ^f   Muñoz, Daniel ^f  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c Laboratori Referencia de Catalunya   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f NONE

Author keywords

Antibodies against oxidized LDL; Glutathione peroxidase; Oxidative stress; Oxidized LDL; Paraoxonase1 activity; Stable coronary heart disease; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; AUTOANTIBODY; BIOLOGICAL MARKER; ENZYME; GLUTATHIONE PEROXIDASE; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CALCULATION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 0038065603     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00053-4     Document Type: Article

References (34)

1. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.
2. Gutteridge J.M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 41:1995;1819-1828.
3. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26:1999;892-904.
4. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
5. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
6. Hulthe J., Wiklund O., Hurt-Camejo E., Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler. Thromb. Vasc. Biol. 21:2001;269-274.
7. Holvoet P., Vanhaecke J., Janssens S., Van de W.F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98:1998;1487-1494.
8. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 103:2001;1955-1960.
9. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20:2000;2243-2247.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
11. McCord J.M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244:1969;6049-6055.
12. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1967;158-169.
13. Vasankari T., Kujala U., Heinonen O., Kapanen J., Ahotupa M. Measurement of serum lipid peroxidation during exercise using three different methods: diene conjugation, thiobarbituric acid reactive material and fluorescent chromolipids. Clin. Chim. Acta. 234:1995;63-69.
14. Senti M., Tomas M., Marrugat J., Elosua R. Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Arterioscler. Thromb. Vasc. Biol. 21:2001;415-420.
15. Zhou X., Zhai X., Ashraf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation. 93:1996;1177-1184.
16. Holvoet P., Stassen J.M., Van Cleemput J., Collen D., Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18:1998;100-107.
17. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21:2001;844-848.
18. Rajman I., Maxwell S., Cramb R., Kendall M. Particle size: the key to the atherogenic lipoprotein? QJM. 87:1994;709-720.
19. Regnstrom J., Nilsson J., Tornvall P., Landou C., Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 339:1992;1183-1186.
20. Tornvall P., Karpe F., Carlson L.A., Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 90:1991;67-80.
21. Junjun W., Yiyi Z., Xiaozhuan L., Daning C. The in vivo oxidized LDL to LDL-cholesterol ratio is correlated with lipid content of LDL. Atherosclerosis. 149:2000;217-218.
22. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14:1994;32-40.
23. Palinski W., Miller E., Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92:1995;821-825.
24. Bergmark C., Wu R., de Faire U., Lefvert A.K., Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15:1995;441-445.
25. Lehtimaki T., Lehtinen S., Solakivi T., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 19:1999;23-27.
26. Puurunen M., Manttari M., Manninen V., et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Int. Med. 154:1994;2605-2609.
27. Wu R., de Faire U., Lemne C., Witztum J.L., Frostegard J. Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension. 33:1999;53-59.
28. Cherubini A., Mecocci P., Senin U., Lowenthal D.T., Barnert G., Chionne F. Autoantibodies against oxidized low-density lipoproteins in older stroke patients. J. Am. Geriatr. Soc. 45:1997;125.
29. Schumacher M., Eber B., Tatzber F., et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic. Biol. Med. 18:1995;1087-1091.
30. Lopes-Virella M.F., Virella G., Orchard T.J., et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90:1999;165-172.
31. Ahmed E., Trifunovic J., Stegmayr B., Hallmans G., Lefvert A.K. Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke. 30:1999;2541-2546.
32. van de Vijver L.P., Steyger R., van Poppel G., et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 122:1996;245-253.
33. Shoji T., Nishizawa Y., Fukumoto M., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 148:2000;171-177.
34. Hulthe J., Wikstrand J., Lidell A., Wendelhag I., Hansson G.K., Wiklund O. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18:1998;1203-1211.